May 5, 2022 02:00 PM EDT
R&D
Pharma

As­traZeneca's Ul­tomiris hits pri­ma­ry end­point for PhI­II NMOSD study

Paul Schloesser

Associate Editor

As­traZeneca caught a trio of re­cent wins — scor­ing an ex­pand­ed in­di­ca­tion for its breast can­cer drug En­her­tu, nail­ing Farx­i­ga’s Phase III win ear­li­er this week …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times